Literature DB >> 19346155

The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.

Criscely L Go1, Raymond L Rosales, Rico J Caraos, Hubert H Fernandez.   

Abstract

OBJECTIVE: To determine the prevalence of and the factors associated with tardive dyskinesia (TD) among Filipino patients with schizophrenia admitted at the National Center for Mental Health. STUDY
DESIGN: Cross-sectional study.
METHODS: A total of 227 inpatients fulfilling the DSM-IV TR criteria for schizophrenia participated in the study. Demographic data including age, disease duration and medication intake were obtained. The Abnormal Involuntary Movement Scale (AIMS) and Simpson Angus Rating Scale (SARS) were performed on all patients. Odds of developing TD in relation to the different variables were computed. The association between study variables and development of TD was also evaluated using the Chi-square test.
FINDINGS: Our cohort of patients had a mean age of 40 (range: 19-73 years old), had a mean disease duration of 6 years, had a daily neuroleptic dose of 700 mg in chlorpromazine equivalent, and had a lifetime neuroleptic exposure of at least 5 years. The prevalence rate of TD was 20.3% (46 out of 227 patients). Fifty-three percent of patients had significant extrapyramidal features (SARS > or =3). TD was noted more in females and older age groups. The other factors associated with TD: were those patients with longer duration of illness and those patients with longer cumulative exposure to neuroleptic drugs. There was no association found with regard to the presence of diabetes mellitus type II, to the use of anticholinergic drugs, to the history of substance abuse and to the history of electroconvulsive therapy.
CONCLUSIONS: Despite the predominant use of first-generation antipsychotic agents, the prevalence of TD among Filipino schizophrenic patients is similar to that reported among Asians, but lower than that reported among our Western counterparts. The results may be affected by differences in methodological, racial and genetic determinants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346155     DOI: 10.1016/j.parkreldis.2009.02.015

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  11 in total

Review 1.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

2.  Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.

Authors:  Renan P Souza; Vincenzo de Luca; Gary Remington; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy; Albert H C Wong
Journal:  Psychopharmacology (Berl)       Date:  2010-04-06       Impact factor: 4.530

3.  Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.

Authors:  Jiajun Weng; Yan Zhang; Huafang Li; Yifeng Shen; Wenjuan Yu
Journal:  Gen Psychiatr       Date:  2019-02-23

4.  Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study.

Authors:  Yirgalem Shewakena Wubeshet; Oumer Sada Mohammed; Tigestu Alemu Desse
Journal:  BMC Psychiatry       Date:  2019-01-18       Impact factor: 3.630

5.  Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study.

Authors:  Rikinkumar S Patel; Zeeshan Mansuri; Amit Chopra
Journal:  Heliyon       Date:  2019-05-17

6.  A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.

Authors:  Maria Cristina B Diaz; Raymond L Rosales
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

7.  Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug.

Authors:  Mohammed A Alblowi; Fahad D Alosaimi
Journal:  Neurosciences (Riyadh)       Date:  2015-10       Impact factor: 0.735

8.  A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.

Authors:  Yanan Huang; Lizhen Pan; Fei Teng; Geying Wang; Chenhu Li; Lingjing Jin
Journal:  Shanghai Arch Psychiatry       Date:  2017-10-25

9.  Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis.

Authors:  Bettina Balint; Helen Killaspy; Louise Marston; Thomas Barnes; Anna Latorre; Eileen Joyce; Caroline S Clarke; Rosa De Micco; Mark J Edwards; Roberto Erro; Thomas Foltynie; Rachael M Hunter; Fiona Nolan; Anette Schrag; Nick Freemantle; Yvonne Foreshaw; Nicholas Green; Kailash P Bhatia; Davide Martino
Journal:  BJPsych Open       Date:  2018-09-27

10.  Assesment of Risk Factors for Tardive Dyskinesia.

Authors:  Melek Kanarya Vardar; Mehmet Emin Ceylan; Bariş Önen Ünsalver
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.